• All News
• Consumer
• Pro
• New Drugs
• Pipeline
• Clinical Trials
• FDA Alerts

Spironolactone Does Not Reduce Risk for Cardiovascular Morbidity, Mortality in Patients on Dialysis

By Elana Gotkine HealthDay Reporter

Medically reviewed by Carmen Pope, BPharm. Last updated on Aug 28, 2025.

THURSDAY, Aug. 28, 2025 -- Spironolactone does not reduce a composite outcome of cardiovascular mortality and hospitalization due to heart failure among patients receiving maintenance dialysis, according to a study published online Aug. 16 in The Lancet and presented at the 62nd European Renal Association Congress, held from June 4 to 7 in Vienna.

Michael Walsh, M.D., Ph.D., from McMaster University in Hamilton, Ontario, Canada, and colleagues conducted an international randomized controlled trial in 143 dialysis programs in 12 countries involving adult patients who were receiving maintenance dialysis for kidney failure for at least three months. Patients who were able to tolerate and adhere to spironolactone 25 mg daily orally during an open-label run-in were randomly assigned to continue spironolactone or matching placebo in a 1:1 ratio (1,260 and 1,278, respectively).

The external safety and efficacy monitoring committee recommended the trial be stopped early for futility after a planned interim analysis of 75 percent of the expected primary outcome events. Patients were followed for a median of 1.8 years. The researchers found that the composite primary outcome of cardiovascular mortality or hospitalization for heart failure occurred in 258 and 276 participants in the spironolactone and placebo groups, respectively (10.46 and 11.33 events per 100 patient-years; hazard ratio, 0.92; 95 percent confidence interval, 0.78 to 1.09). Death from any cause and hospitalization from any cause were similar between the groups.

"While the results are not what we wanted, they provide much-needed clarity. This study moves us one step closer to finding effective and safe treatments for a group that urgently needs them," Walsh said in a statement.

Several authors disclosed ties to the biopharmaceutical industry.

Abstract/Full Text (subscription or payment may be required)

More Information

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2025 HealthDay. All rights reserved.

Posted August 2025

More news resources

• FDA Medwatch Drug Alerts
• Daily MedNews
• News for Health Professionals
• New Drug Approvals
• New Drug Applications
• Drug Shortages
• Clinical Trial Results
• Generic Drug Approvals

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.